1. The median follow-up period for health-related quality-of-life (HRQOL) outcomes analyses was 12.9 months 2. For all FKSI-DRS, EORTC QLQ-C30...

1. The median overall survival for pembrolizumab versus chemotherapy was not statistically significant difference. 2. Common grade 3 or higher...

1. The failure-free-survival at 3 years for induction chemotherapy with paclitaxel, cisplatin and capecitabine group was 83.5% versus 68.9% in...

1. The median progression-free survival was 7.4 months in the rucaparib group and 5.7 months in the chemotherapy group for...

1. The overall response rate was 54.8% in the intention-to-treat group while it was 59.0% in the efficacy-evaluable group. 2....

1. Nivolumab in combination with chemotherapy or ipilimumab significantly prolonged overall survival compared to chemotherapy alone. 2. Common treatment-related adverse...

1. The overall progression-free survival (PFS) was 10.54 years. 2. Patients with body mass weight (BMI) ≥ 24 derived greater...

1. The overall response rate (ORR) was 25.6%, with 8.0% of the patients achieved complete response. 2. Common treatment-related adverse...

1. The median overall survival for nivolumab was 16.4 months and for sorafenib was 14.7 months 2. Patients receiving nivolumab...

1. The 6.5-year progression-free survival for the nivolumab combination group, nivolumab group and in the ipilimumab group were 34%, 29%...